247 related articles for article (PubMed ID: 26165688)
1. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
2. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Koh Y; Kim TM; Jeon YK; Kwon TK; Hah JH; Lee SH; Kim DW; Wu HG; Rhee CS; Sung MW; Kim CW; Kim KH; Heo DS
Ann Oncol; 2009 Aug; 20(8):1414-9. PubMed ID: 19468031
[TBL] [Abstract][Full Text] [Related]
3. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
4. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Zhang Z; Jiang C; Hu L
Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
Bai ZL; Wang YY; Zhe H; He JL; Hai P
Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
[TBL] [Abstract][Full Text] [Related]
6. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
7. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
8. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
11. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
[TBL] [Abstract][Full Text] [Related]
15. Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy.
Zhang S; Li Q; Zhang Q; Wang J; Zhang H; Zhang Z; Wang Q; Yang X; Gu Y; Zhang H
Int J Biol Markers; 2010; 25(3):141-9. PubMed ID: 20878620
[TBL] [Abstract][Full Text] [Related]
16. Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen.
Leone J; Perez JE; Dominguez ME; Iturbe J; Leone JP; Mac Donnell MC; Grosman G; Vallejo CT; Leone BA; Zwenger AO
Int J Biol Markers; 2016 Jul; 31(3):e300-8. PubMed ID: 27197582
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
19. Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy?
Polat G; Yılmaz U; Anar C; Kömürcüoğlu B; Aydoğdu Z
Indian J Cancer; 2015; 52(3):277-80. PubMed ID: 26905109
[TBL] [Abstract][Full Text] [Related]
20. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
